drug
(daratumumab + hyaluronidase (human recombinant))
Marketedupdated 3mo agoby Janssen Biotech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugdaratumumab31 co-mentions · 16 sources
- drugdaratumumab + Gene Therapy31 co-mentions · 16 sources
- drugDARZALEX FASPRO30 co-mentions · 15 sources
- tagApproval30 co-mentions · 15 sources
- companyJanssen Biotech Inc15 co-mentions · 15 sources
- tagOncology2 co-mentions · 1 sources
- tagMultiple Myeloma2 co-mentions · 1 sources
- companyNational Cancer Institute US1 co-mentions · 1 sources
all catalysts(16)
approval · 15
May 1, 2020
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Jan 11, 2021
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Jan 15, 2021
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Feb 8, 2021
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Mar 12, 2021
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Jul 9, 2021
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Nov 30, 2021
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Jan 21, 2022
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Nov 2, 2022
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Jul 30, 2024
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Nov 6, 2025
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Nov 14, 2025
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Nov 19, 2025
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Jan 27, 2026
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Feb 12, 2026
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Trials studying (daratumumab + hyaluronidase (human recombinant))
- phase1A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- EP1Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- phase3A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
- phase1A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults
- phase3To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that